{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:37:21Z","timestamp":1791992241371,"version":"4.4.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS079697"],"award-info":[{"award-number":["R01NS079697"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["5UE5NS070680-15"],"award-info":[{"award-number":["5UE5NS070680-15"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA260443"],"award-info":[{"award-number":["R01CA260443"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma is a lethal brain tumor that is resistant to conventional therapies. Here we present a non-lytic replicating retrovirus (RRV) that delivers an IL-15-receptor-linked fusion protein (RLI) superagonist directly into glioblastoma cells, creating localized immunotherapy biofactories. In orthotopic mouse models, RRV-RLI dramatically suppresses tumor growth, prolongs survival, and induces lasting remission with immunologic memory. Mechanistically, we observe increased CD8\u207a T cell and natural killer cell infiltration and activation, alongside elevated antigen presentation pathways. Combining RRV-RLI with temozolomide, which is standard-of-care chemotherapy for glioblastoma, enhances antitumor immunity. T cell receptor sequencing reveals a polyclonal repertoire of T cells, enhanced by combining RRV-RLI with temozolomide. Analysis of the T-cell repertoire suggests it to be directed against tumor rather than viral antigens, supporting the specificity and re-applicability of our approach. These findings illustrate that RRV-RLI reprograms glioblastoma into an immunostimulatory hub, offering a viral immunotherapy against glioblastoma and potentially other therapy-resistant solid tumors.<\/jats:p>","DOI":"10.1038\/s41467-026-72746-5","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:46:07Z","timestamp":1779209167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Non-lytic viral immunotherapy induces long-term glioblastoma survival and tumor-specific immunity without eliciting an antiviral response"],"prefix":"10.1038","volume":"17","author":[{"given":"Alexander F.","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9411-9881","authenticated-orcid":false,"given":"Atul","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3805-431X","authenticated-orcid":false,"given":"Isabella","family":"Lovalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabraj","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan L.","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poojan","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9256-9233","authenticated-orcid":false,"given":"Jinpyo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlina","family":"Chuntova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meeki","family":"Lad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-2176","authenticated-orcid":false,"given":"Robert","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Shu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2114-2094","authenticated-orcid":false,"given":"Melissa","family":"Sathavipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saket","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chalif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-911X","authenticated-orcid":false,"given":"Noriyuki","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2949-2227","authenticated-orcid":false,"given":"Manish K.","family":"Aghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"72746_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"72746_CR2","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom, Q. T. et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro. Oncol. 21, v1\u2013v100 (2019).","journal-title":"Neuro. Oncol."},{"key":"72746_CR3","doi-asserted-by":"crossref","unstructured":"Young, J. S., Dayani, F., Morshed, R. A., Okada, H. & Aghi, M. K. Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. World Neurosurg. 124, 397\u2013409 (2019).","DOI":"10.1016\/j.wneu.2018.12.222"},{"key":"72746_CR4","doi-asserted-by":"publisher","unstructured":"Reardon, D. A. et al. Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1024 (2020).","DOI":"10.1001\/jamaoncol.2020.1024"},{"key":"72746_CR5","doi-asserted-by":"publisher","unstructured":"Montoya, M. L., Kasahara, N. & Okada, H. Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. Neurooncol. Pract. https:\/\/doi.org\/10.1093\/NOP\/NPAA007.","DOI":"10.1093\/NOP\/NPAA007"},{"key":"72746_CR6","doi-asserted-by":"crossref","unstructured":"Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A. & Fecci, P. E. T-Cell dysfunction in glioblastoma: Applying a new framework. Clin. Cancer Res. 24, 3792\u20133802 (2018).","DOI":"10.1158\/1078-0432.CCR-18-0047"},{"key":"72746_CR7","doi-asserted-by":"crossref","unstructured":"Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G. & von Deimling, A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 129, 829\u2013848 (2015).","DOI":"10.1007\/s00401-015-1432-1"},{"key":"72746_CR8","doi-asserted-by":"crossref","unstructured":"D\u2019Alessio, A., Proietti, G., Sica, G. & Scicchitano, B. M. Pathological and molecular features of glioblastoma and its peritumoral tissue. Cancers (Basel). 11, 469 (2019).","DOI":"10.3390\/cancers11040469"},{"key":"72746_CR9","doi-asserted-by":"publisher","first-page":"8304","DOI":"10.1158\/1078-0432.CCR-04-2588","volume":"11","author":"A Facoetti","year":"2005","unstructured":"Facoetti, A. et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin. Cancer Res. 11, 8304\u20138311 (2005).","journal-title":"Clin. Cancer Res."},{"key":"72746_CR10","doi-asserted-by":"crossref","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","DOI":"10.1126\/science.aar3593"},{"key":"72746_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"M Lim","year":"2018","unstructured":"Lim, M., Xia, Y., Bettegowda, C. & Weller, M. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 15, 422\u2013442 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72746_CR12","doi-asserted-by":"crossref","unstructured":"Alban, T. J. et al. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight 3, e122264 (2018).","DOI":"10.1172\/jci.insight.122264"},{"key":"72746_CR13","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","volume":"24","author":"K Woroniecka","year":"2018","unstructured":"Woroniecka, K. et al. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin. Cancer Res. 24, 4175\u20134186 (2018).","journal-title":"Clin. Cancer Res."},{"key":"72746_CR14","doi-asserted-by":"crossref","unstructured":"Haddad, A. F. et al. Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma. Sci. Rep. 10, 17580 (2020).","DOI":"10.1038\/s41598-020-73793-8"},{"key":"72746_CR15","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","volume":"24","author":"P Chongsathidkiet","year":"2018","unstructured":"Chongsathidkiet, P. et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 24, 1459\u20131468 (2018).","journal-title":"Nat. Med."},{"key":"72746_CR16","doi-asserted-by":"publisher","first-page":"91779","DOI":"10.18632\/oncotarget.21586","volume":"8","author":"AC Filley","year":"2017","unstructured":"Filley, A. C., Henriquez, M. & Dey, M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 8, 91779\u201391794 (2017).","journal-title":"Oncotarget"},{"key":"72746_CR17","first-page":"86","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy, L. B. & Salama, A. K. S. A review of cancer immunotherapy toxicity. CA Cancer J. Clin. 70, 86\u2013104 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"72746_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2020.11.FOCUS20859","volume":"50","author":"AF Haddad","year":"2021","unstructured":"Haddad, A. F., Young, J. S. & Aghi, M. K. Using viral vectors to deliver local immunotherapy to glioblastoma. Neurosurg. Focus 50, 1\u20137 (2021).","journal-title":"Neurosurg. Focus"},{"key":"72746_CR19","doi-asserted-by":"publisher","unstructured":"Haddad, A. F., Young, J. S., Mummaneni, N. V, Kasahara, N. & Aghi, M. K. Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies. J. Neurooncol. https:\/\/doi.org\/10.1007\/s11060-020-03684-5 (2021).","DOI":"10.1007\/s11060-020-03684-5"},{"key":"72746_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/B978-0-12-386509-0.00011-9","volume":"507","author":"CR Logg","year":"2012","unstructured":"Logg, C. R., Robbins, J. M., Jolly, D. J., Gruber, H. E. & Kasahara, N. Retroviral Replicating Vectors in Cancer. Methods Enzymol. 507, 199\u2013228 (2012).","journal-title":"Methods Enzymol."},{"key":"72746_CR21","doi-asserted-by":"publisher","first-page":"10066","DOI":"10.1128\/JVI.02300-13","volume":"88","author":"AH Lin","year":"2014","unstructured":"Lin, A. H. et al. Blockade of Type I Interferon (IFN) Production by Retroviral Replicating Vectors and Reduced Tumor Cell Responses to IFN Likely Contribute To Tumor Selectivity. J. Virol. 88, 10066\u201310077 (2014).","journal-title":"J. Virol."},{"key":"72746_CR22","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-18-0619","volume":"24","author":"DJ Hogan","year":"2018","unstructured":"Hogan, D. J. et al. Molecular analyses support the safety and activity of retroviral replicating vector toca 511 in patients. Clin. Cancer Res. 24, 4680\u20134693 (2018).","journal-title":"Clin. Cancer Res."},{"key":"72746_CR23","doi-asserted-by":"crossref","unstructured":"Cloughesy, T. F. et al. Effect of Vocimagene Amiretrorepvec in Combination with Flucytosine vs Standard of Care on Survival following Tumor Resection in Patients with Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 6, 1939\u20131946 (2020).","DOI":"10.1001\/jamaoncol.2020.3161"},{"key":"72746_CR24","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/14712598.2021.1902982","volume":"21","author":"SA Collins","year":"2021","unstructured":"Collins, S. A., Shah, A. H., Ostertag, D., Kasahara, N. & Jolly, D. J. Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer. Expert Opin. Biol. Ther. 21, 1199\u20131214 (2021).","journal-title":"Expert Opin. Biol. Ther."},{"key":"72746_CR25","doi-asserted-by":"crossref","unstructured":"Berraondo, P. et al. Cytokines in clinical cancer immunotherapy. Br. J. Cancer 120, 6\u201315 (2019).","DOI":"10.1038\/s41416-018-0328-y"},{"key":"72746_CR26","doi-asserted-by":"crossref","unstructured":"Desbois, M. et al. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: Implications for antimetastatic treatment. J. Immunother. Cancer 8, 632 (2020).","DOI":"10.1136\/jitc-2020-000632"},{"key":"72746_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4049\/jimmunol.1600019","volume":"197","author":"M Desbois","year":"2016","unstructured":"Desbois, M. et al. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector\/Memory CD8\u2009+\u2009T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists. J. Immunol. 197, 168\u2013178 (2016).","journal-title":"J. Immunol."},{"key":"72746_CR28","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1158\/1535-7163.MCT-09-0275","volume":"8","author":"A Bessard","year":"2009","unstructured":"Bessard, A., Sole, V., Bouchaud, G., Quemener, A. & Jacques, Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor fusion protein, in metastatic melanoma and colorectal cancer. Mol. Cancer Ther. 8, 2736\u20132745 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"72746_CR29","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.celrep.2017.10.030","volume":"21","author":"S Darmanis","year":"2017","unstructured":"Darmanis, S. et al. Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma. Cell Rep. 21, 1399\u20131410 (2017).","journal-title":"Cell Rep."},{"key":"72746_CR30","unstructured":"Paxton, R. J. Measurement of interleukin 15. Curr. Protoc. Immunol. Chapter 6, (2001)."},{"key":"72746_CR31","doi-asserted-by":"publisher","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon, S. & Labarriere, N. PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? Oncoimmunology 7, e1364828 (2017).","journal-title":"Oncoimmunology"},{"key":"72746_CR32","doi-asserted-by":"crossref","unstructured":"Getu, A. A. et al. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol. Cancer 22, 1\u201315 (2023).","DOI":"10.1186\/s12943-023-01751-9"},{"key":"72746_CR33","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","volume":"22","author":"E Picarda","year":"2016","unstructured":"Picarda, E., Ohaegbulam, K. C. & Zang, X. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clin. Cancer Res. 22, 3425 (2016).","journal-title":"Clin. Cancer Res."},{"key":"72746_CR34","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-11-0677","volume":"11","author":"DS Vinay","year":"2012","unstructured":"Vinay, D. S. & Kwon, B. S. Immunotherapy of cancer with 4-1BB. Mol. Cancer Ther. 11, 1062\u20131070 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"72746_CR35","doi-asserted-by":"crossref","unstructured":"Haddad, A. F., Young, J. S., Gill, S. & Aghi, M. K. Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions. Semin. Cancer Biol. 10.1016\/J.SEMCANCER.2022.02.019 (2022)","DOI":"10.1016\/j.semcancer.2022.02.019"},{"key":"72746_CR36","first-page":"1","volume":"3","author":"AF Haddad","year":"2021","unstructured":"Haddad, A. F. et al. Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neurooncol. Adv. 3, 1\u201316 (2021).","journal-title":"Neurooncol. Adv."},{"key":"72746_CR37","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","volume":"17","author":"SP Haen","year":"2020","unstructured":"Haen, S. P., L\u00f6ffler, M. W., Rammensee, H. G. & Brossart, P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat. Rev. Clin. Oncol. 17, 595\u2013610 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72746_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8\u2009+\u2009T cell exhaustion. Nature 571, 211 (2019).","journal-title":"Nature"},{"key":"72746_CR39","doi-asserted-by":"crossref","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data. Nat. Communi. 13, 1\u201310 (2022).","DOI":"10.1038\/s41467-022-28803-w"},{"key":"72746_CR40","doi-asserted-by":"crossref","unstructured":"Jurga, A. M., Paleczna, M. & Kuter, K. Z. Overview of General and Discriminating Markers of Differential Microglia Phenotypes. Front. Cell. Neurosci. 14, 198 (2020).","DOI":"10.3389\/fncel.2020.00198"},{"key":"72746_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/JLB.3RU1018-378RR","volume":"106","author":"L Wang","year":"2019","unstructured":"Wang, L. et al. M2b macrophage polarization and its roles in diseases. J. Leukoc. Biol. 106, 345\u2013358 (2019).","journal-title":"J. Leukoc. Biol."},{"key":"72746_CR42","doi-asserted-by":"crossref","unstructured":"Ochocka, N. et al. Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages. Nat. Commun. 12, 1\u201314 (2021).","DOI":"10.1038\/s41467-021-21407-w"},{"key":"72746_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ccell.2022.12.007","volume":"41","author":"M Kilian","year":"2023","unstructured":"Kilian, M. et al. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer Cell 41, 235\u2013251.e9 (2023).","journal-title":"Cancer Cell"},{"key":"72746_CR44","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/neuonc\/nox165","volume":"20","author":"F Szulzewsky","year":"2017","unstructured":"Szulzewsky, F. et al. Loss of host-derived osteopontin creates a glioblastoma-promoting microenvironment. Neuro. Oncol. 20, 355 (2017).","journal-title":"Neuro. Oncol."},{"key":"72746_CR45","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.4049\/jimmunol.1500623","volume":"194","author":"M Inoue","year":"2015","unstructured":"Inoue, M. & Shinohara, M. L. Role of osteopontin and integrin alpha-v in T cell-mediated anti-inflammatory responses in endotoxemia. J. Immunol. 194, 5595 (2015).","journal-title":"J. Immunol."},{"key":"72746_CR46","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/1078-0432.CCR-22-2469","volume":"29","author":"ML Frank","year":"2023","unstructured":"Frank, M. L. et al. T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy. Clin. Cancer Res. 29, 994 (2023).","journal-title":"Clin. Cancer Res."},{"key":"72746_CR47","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1093\/bioinformatics\/btx286","volume":"33","author":"N Tickotsky","year":"2017","unstructured":"Tickotsky, N., Sagiv, T., Prilusky, J., Shifrut, E. & Friedman, N. McPAS-TCR: a manually curated catalogue of pathology-associated T cell receptor sequences. Bioinformatics 33, 2924\u20132929 (2017).","journal-title":"Bioinformatics"},{"key":"72746_CR48","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1600-065X.2008.00604.x","volume":"222","author":"MA \u2018Mac\u2019 Cheever","year":"2008","unstructured":"\u2018Mac\u2019 Cheever, M. A. Twelve immunotherapy drugs that could cure cancers. Immunol. Rev. 222, 357\u2013368 (2008).","journal-title":"Immunol. Rev."},{"key":"72746_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/156652313804806561","volume":"13","author":"CM Ochoa","year":"2013","unstructured":"Ochoa, C.M. et al. Interleukin-15 in Gene Therapy of cancer. Curr. Gene Ther. 13, 15\u201330 (2013).","journal-title":"Curr. Gene Ther."},{"key":"72746_CR50","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/0008-5472.CAN-15-1498","volume":"75","author":"K Pilipow","year":"2015","unstructured":"Pilipow, K. et al. IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. Cancer Res. 75, 5187\u20135193 (2015).","journal-title":"Cancer Res"},{"key":"72746_CR51","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cytogfr.2011.04.001","volume":"22","author":"M Jakobisiak","year":"2011","unstructured":"Jakobisiak, M., Golab, J. & Lasek, W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 22, 99\u2013108 (2011).","journal-title":"Cytokine Growth Factor Rev."},{"key":"72746_CR52","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","volume":"3","author":"TA Waldmann","year":"2015","unstructured":"Waldmann, T. A. The shared and contrasting roles of interleukin-2 (IL-2) and IL-15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol. Res. 3, 219 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"72746_CR53","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","volume":"11","author":"TA Waldmann","year":"2020","unstructured":"Waldmann, T. A., Dubois, S., Miljkovic, M. D. & Conlon, K. C. IL-15 in the Combination Immunotherapy of Cancer. Front. Immunol. 11, 868 (2020).","journal-title":"Front. Immunol."},{"key":"72746_CR54","doi-asserted-by":"crossref","unstructured":"Bergamaschi, C. et al. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-\u03b3, CXCL9 and CXCL10. J. Immunother. Cancer 8, e000599 (2020).","DOI":"10.1136\/jitc-2020-000599"},{"key":"72746_CR55","doi-asserted-by":"publisher","first-page":"6239","DOI":"10.1136\/jitc-2022-006239","volume":"11","author":"M Zannikou","year":"2023","unstructured":"Zannikou, M. et al. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. J. Immunother. Cancer 11, 6239 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"72746_CR56","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1046\/j.1365-2249.2001.01672.x","volume":"126","author":"KU Saikh","year":"2001","unstructured":"Saikh, K. U., Khan, A. S., Kissner, T. & Ulrich, R. G. IL-15-induced conversion of monocytes to mature dendritic cells. Clin. Exp. Immunol. 126, 447 (2001).","journal-title":"Clin. Exp. Immunol."},{"key":"72746_CR57","doi-asserted-by":"publisher","first-page":"e1501137","DOI":"10.1080\/2162402X.2018.1501137","volume":"7","author":"V Genoud","year":"2018","unstructured":"Genoud, V. et al. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Oncoimmunology 7, e1501137 (2018).","journal-title":"Oncoimmunology"},{"key":"72746_CR58","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bpa.12927","volume":"31","author":"M Gonz\u00e1lez-Tablas Pimenta","year":"2021","unstructured":"Gonz\u00e1lez-Tablas Pimenta, M. et al. Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome. Brain Pathol. 31, 365\u2013380 (2021).","journal-title":"Brain Pathol."},{"key":"72746_CR59","doi-asserted-by":"crossref","unstructured":"Ohteki, T., Suzue, K., Maki, C., Ota, T. & Koyasu, S. Critical role of IL-15\u2013IL-15R for antigen-presenting cell functions in the innate immune response. Nat. Immunol. 2, 1138\u20131143 (2001).","DOI":"10.1038\/ni729"},{"key":"72746_CR60","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ijc.29686","volume":"138","author":"D Mathios","year":"2016","unstructured":"Mathios, D. et al. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int. J. Cancer 138, 187\u2013194 (2016).","journal-title":"Int. J. Cancer"},{"key":"72746_CR61","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/ijc.10395","volume":"99","author":"T Yajima","year":"2002","unstructured":"Yajima, T. et al. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int. J. Cancer 99, 573\u2013578 (2002).","journal-title":"Int. J. Cancer"},{"key":"72746_CR62","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1158\/0008-5472.CAN-08-0045","volume":"68","author":"M Epardaud","year":"2008","unstructured":"Epardaud, M. et al. Interleukin-15\/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8\u2009+\u2009T cells. Cancer Res. 68, 2972\u20132983 (2008).","journal-title":"Cancer Res"},{"key":"72746_CR63","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/neuonc\/noq157","volume":"13","author":"JH Sampson","year":"2011","unstructured":"Sampson, J. H. et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro. Oncol. 13, 324 (2011).","journal-title":"Neuro. Oncol."},{"key":"72746_CR64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11060-020-03598-2","volume":"151","author":"KM Hotchkiss","year":"2021","unstructured":"Hotchkiss, K. M. & Sampson, J. H. Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. J. Neurooncol. 151, 55\u201362 (2021).","journal-title":"J. Neurooncol."},{"key":"72746_CR65","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jhep.2019.05.015","volume":"71","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. TOX promotes the exhaustion of antitumor CD8\u2009+\u2009T cells by preventing PD1 degradation in hepatocellular carcinoma. J. Hepatol. 71, 731\u2013741 (2019).","journal-title":"J. Hepatol."},{"key":"72746_CR66","doi-asserted-by":"crossref","unstructured":"Hirst, T. C. et al. Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? Br. J. Cancer 108, 64\u201371 (2013).","DOI":"10.1038\/bjc.2012.504"},{"key":"72746_CR67","doi-asserted-by":"publisher","first-page":"33165","DOI":"10.18632\/oncotarget.5320","volume":"6","author":"MR Patel","year":"2015","unstructured":"Patel, M. R. et al. Vesicular stomatitis virus expressing interferon-\u03b2 is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. Oncotarget 6, 33165 (2015).","journal-title":"Oncotarget"},{"key":"72746_CR68","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1158\/1078-0432.CCR-18-3626","volume":"26","author":"B Tang","year":"2020","unstructured":"Tang, B. et al. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma. Clin. Cancer Res. 26, 2216\u20132230 (2020).","journal-title":"Clin. Cancer Res."},{"key":"72746_CR69","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","volume":"81","author":"R Ma","year":"2021","unstructured":"Ma, R. et al. An Oncolytic Virus Expressing IL15\/IL15R\u03b1 Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma. Cancer Res. 81, 3635\u20133648 (2021).","journal-title":"Cancer Res"},{"key":"72746_CR70","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","volume":"17","author":"A Lemos de Matos","year":"2020","unstructured":"Lemos de Matos, A., Franco, L. S. & McFadden, G. Oncolytic Viruses and the Immune System: The Dynamic Duo. Mol. Ther. Methods Clin. Dev. 17, 349 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"72746_CR71","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1038\/nm.3013","volume":"18","author":"CA Alvarez-Breckenridge","year":"2012","unstructured":"Alvarez-Breckenridge, C. A. et al. NK cells impede glioblastoma virotherapy via NKp30 and NKp46 natural cytotoxicity receptors. Nat. Med. 18, 1827 (2012).","journal-title":"Nat. Med."},{"key":"72746_CR72","doi-asserted-by":"crossref","unstructured":"Webb, M. J. et al. Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response. Nat. Commun. 15, 5442 (2024).","DOI":"10.1038\/s41467-024-49286-x"},{"key":"72746_CR73","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1158\/0008-5472.CAN-15-0894","volume":"75","author":"J Han","year":"2015","unstructured":"Han, J. et al. TGF-\u03b2 treatment enhances glioblastoma virotherapy by inhibiting the innate immune response. Cancer Res. 75, 5273 (2015).","journal-title":"Cancer Res"},{"key":"72746_CR74","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/mt.2012.83","volume":"20","author":"OD Perez","year":"2012","unstructured":"Perez, O. D. et al. Design and selection of toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression. Mol. Ther. 20, 1689\u20131698 (2012).","journal-title":"Mol. Ther."},{"key":"72746_CR75","doi-asserted-by":"publisher","first-page":"103382","DOI":"10.1016\/j.xpro.2024.103382","volume":"5","author":"M Ashayeripanah","year":"2024","unstructured":"Ashayeripanah, M. & Villadangos, J. A. Protocol to study ex vivo T cell priming by conventional dendritic cells from the mouse spleen. STAR Protoc. 5, 103382 (2024).","journal-title":"STAR Protoc."},{"key":"72746_CR76","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley, K. A. et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173, 291\u2013304.e6 (2018).","journal-title":"Cell"},{"key":"72746_CR77","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/1078-0432.CCR-20-1163","volume":"27","author":"A Pender","year":"2021","unstructured":"Pender, A. et al. Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Clin. Cancer Res. 27, 202\u2013212 (2021).","journal-title":"Clin. Cancer Res."},{"key":"72746_CR78","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72746-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72746-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72746-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:02:47Z","timestamp":1784563367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72746-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72746"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72746-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K.A., N.K., A.F.H., and S.C. are co-founders and consultants for Kopra Bio, a startup company founded in summer 2024 based on the work presented in this manuscript. S.C. is an employee of 4D Molecular Therapeutics. M.S. is an employee of Kopra Bio. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6613"}}